The takeaway
Jade Biosciences, Inc. shows a pronounced seasonal pattern over 5 years of data — strongest in March (+26.9%) and softest in May (−18.5%).
Right now
In July, the stock has fallen 40% of years, averaging −6.9%, roughly 9.0 pts behind the S&P 500.
The full picture
Jade Biosciences, Inc.'s most dependable month has been March, higher in 3 of 4 years; May has been its least reliable, up just 0% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | — | — | — | — | — | — |
Month by month
The stock's clearest edge over the S&P 500 lands in March (+25.8 pts); it has trailed the market most in May (−19.2 pts).
“vs S&P” is Jade Biosciences, Inc.’s average for a month minus the S&P 500’s average for that same month — isolating Jade Biosciences, Inc.’s own seasonal edge from broad market drift.
Reality check
Over the last 4 years, March has closed higher 75% of the time versus 75% across the last 5 years — the pattern is holding.
Figures are the typical (median) March return and how often it rose — the last 4 years versus the last 5(the heatmap’s default window). This verdict stays anchored to that 5-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
The seasonal story is really one month's story — March. It has closed higher in 3 of 4 Marches, a concentration the rest of the calendar can't touch.
Read it with one caveat: the average (+26.9%) runs well ahead of the median (+14.3%), so a handful of outsized years — not steady strength — do much of the lifting. That reliability comes with real swings, mind — even March ranges by 37.9% from year to year, so any single year can land far from the average. Better still, that strength is the stock's own and not just a buoyant market — March has outpaced the S&P 500 by +25.8 points on average. Few peers keep such company in March — the typical stock clears it just 56% of the time.
It doesn't stand entirely alone — June, August, and September have leaned firm as well, if less emphatically. At the other end of the calendar, May has been the soft spot — the weakest of 5 months that average a loss (−18.5%), and the edge isn't year-round — the stock has trailed the S&P 500 in May, April, and July. Its roughest month on record was a −90.4% June in 2024 — a reminder of how hard even a seasonal name can fall.
For a stock this dependable in March, the sharper question is the rest of the year — outside its strong stretch, the calendar gives far less to lean on. With a short 5-year record and returns that swing hard year to year, the signal is best held loosely.
Short answers on the stock's best month (March), its worst (May), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2021 its best month (March, +26.9%) has run well ahead of its worst (May, −18.5%) — the heatmap above shows how steady that gap has been year to year.
March has been the strongest, averaging +26.9% and closing higher in 3 of 4 years since 2021.
It's the weakest, averaging −18.5% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade